(Q38219010)

31 August 2017

title

Challenges in mucosal vaccines for the control of infectious diseases (English)

1 reference

31 August 2017

Tatsuhiko Azegami

1

1 reference

31 August 2017

Yoshikazu Yuki

series ordinal

2

1 reference

31 August 2017

Hiroshi Kiyono

series ordinal

3

1 reference

31 August 2017

language of work or name

1 reference

9 June 2014

1 reference

31 August 2017

published in

International Immunology

1 reference

31 August 2017

volume

26

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

517-528

1 reference

Edward jenner and the small pox vaccine

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Designing tomorrow's vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Mucosal immunity: its role in defense and allergy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Global, regional, and national causes of child mortality in 2008: a systematic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Mucosal vaccines: novel advances in technology and delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Mucosal immunity and vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Adhesion receptors of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Overview of new vaccines and technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Actions of cholera toxin and the prevention and treatment of cholera

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Stimulation of intestinal mucosal adenyl cyclase by cholera enterotoxin and prostaglandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Development of improved cholera vaccine based on subunit toxoid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Field trial of oral cholera vaccines in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Oral vaccines against cholera

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Isolation and Characterization of Gal E Mutant Ty 21a of Salmonella typhi: A Candidate Strain for a Live, Oral Typhoid Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Priming of Salmonella enterica serovar typhi-specific CD8(+) T cells by suicide dendritic cell cross-presentation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Heterogeneity of multifunctional IL-17A producing S. Typhi-specific CD8+ T cells in volunteers following Ty21a typhoid immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Cross-reactive gut-directed immune response against Salmonella enterica serovar Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Phosphoantigen-expanded human gammadelta T cells display potent cytotoxicity against monocyte-derived macrophages infected with human and avian influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Comparative efficacy of inactivated and live attenuated influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Virological Surveillance of Influenza Viruses during the 2008-09, 2009-10 and 2010-11 Seasons in Tunisia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Mucosal immunity to poliovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Immunogenicity and safety of live oral attenuated bovine rotavirus vaccine strain RIT 4237 in adults and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Failure of live, attenuated oral rotavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Intussusception after administration of the rhesus tetravalent rotavirus vaccine (Rotashield): the search for a pathogenic mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Efficacy and safety of an oral live attenuated human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in Latin American infants: a randomised, double-blind, placebo-controlled phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Rotavirus vaccines: how they work or don't work

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Intussusception risk after rotavirus vaccination in U.S. infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Risk of intussusception after monovalent rotavirus vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Rotavirus vaccines--balancing intussusception risks and health benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

A low gastric pH mouse model to evaluate live attenuated bacterial vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Preparation of double liposomes and their efficiency as an oral vaccine carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Regulation of intestinal homeostasis by innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Control of rheumatoid arthritis by oral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Perspectives on mucosal vaccines: is mucosal tolerance a barrier?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Failure to induce oral tolerance to a soluble protein in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

The B subunit of Escherichia coli heat labile enterotoxin abrogates oral tolerance, promoting predominantly Th2‐type immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Secretory IgA-mediated protection against V. cholerae and heat-labile enterotoxin-producing enterotoxigenic Escherichia coli by rice-based vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Intranasal vaccination with an inactivated whole influenza virus vaccine induces strong antibody responses in serum and nasal mucus of healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Influenza vaccine: split-product versus whole-virus types--How do they differ

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Phase I/II trial of a replication-deficient trivalent influenza virus vaccine lacking NS1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Sublingual vaccination with influenza virus protects mice against lethal viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Intrarectal immunization and IgA antibody-secreting cell homing to the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Intravaginal administration of an inactivated vaccine prevents lesions induced by caprine herpesvirus-1 in goats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Eye mucosa: an efficient vaccine delivery route for inducing protective immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Id2-, RORgammat-, and LTbetaR-independent initiation of lymphoid organogenesis in ocular immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINTIMM%2FDXU063

21 January 2018

Identifiers

DOI

10.1093/INTIMM/DXU063

1 reference

31 August 2017

1 reference